ABSTRACT
Backgound Accurate assessment of diastolic function and left ventricular (LV) filling pressure is central to heart failure diagnosis and risk stratification. Contemporary guideline algorithms rely on complex parameters that are not consistently available in routine clinical practice.
Objective To compare the diagnostic and prognostic performance of the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging (ASE/EACVI) and 2025 ASE guidelines with a deep learning model based on routinely acquired echocardiographic variables.
Methods This study evaluated the guideline-based algorithms and a deep learning model in participants from the Atherosclerosis Risk in Communities (ARIC) cohort (n=5450) for prognostication and two invasive hemodynamic validation cohorts from the United States (n=83) and Japan (n=130) for detection of elevated left ventricular filling pressure.
Results In the ARIC cohort, the deep learning model demonstrated superior prognostic performance compared with the 2016 and 2025 guidelines (C-index: 0.676 vs. 0.638 and 0.602, respectively; both p<0.001). Similar findings were observed among participants with preserved ejection fraction (C-index: 0.660 vs. 0.628 and 0.590; both p<0.001), with improved performance compared with the H2FPEF score (C-index: 0.660 vs. 0.607; p<0.001). In the US hemodynamic validation cohort, the deep learning model showed higher diagnostic performance than the 2025 guidelines (AUC: 0.879 vs. 0.822; p=0.041) and similar performance compared with the 2016 guidelines (AUC: 0.879 vs. 0.812; p=0.138). In the Japanese hemodynamic validation cohort, the deep learning model outperformed both guidelines (AUC: 0.816 vs. 0.634 and 0.694; both p<0.05).
Conclusions A deep learning model leveraging routinely available echocardiographic parameters demonstrated improved diagnostic and prognostic performance compared with contemporary guideline-based approaches, potentially offering a scalable alternative for assessing diastolic function and left ventricular filling pressures.
Competing Interest Statement
Dr. Tokodi was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences and implemented the MILAB project (Project No. RRF-2.3.1-21-2022-00004) with support from the European Union. Dr. Kagiyama received research grants from AstraZeneca, Bristol Myers Squibb, EchoNous Inc., and AMI Inc., speaker honoraria from Eli Lilly, Novartis, Otsuka Pharmaceutical, Bristol Myers Squibb, and Boehringer-Ingelheim, and was affiliated with a department funded by Paramount Bed Ltd. Dr. Pandey is a consultant for Tricog, MedicalAI, Anumana, and Ultromics. Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore, has received research support from Novo Nordisk and Roche Diagnostics, and has served in advisory and consulting roles for various pharmaceutical and research organizations. She is the co-founder and non-executive director of Us2.ai and a co-inventor of Us2.ai patents (US 10,631,828 B1; US 10,702,247 B2; US 11,301,996 B2; US 11,446,009 B2; US 11,931,207 B2; US 12,001,939). Dr. Yanamala has received grants or contracts from MindMics, RCE Technologies, HeartSciences, and Abiomed, consulting fees from Turnkey Learning and Turnkey Insights, and honoraria or travel support from West Virginia University and the National Science Foundation. She is an advisor to Research Spark Hub and Magnetic 3D, a faculty member at Carnegie Mellon University, an editorial board member of the American Society of Echocardiography, and a special government employee at the FDA Center for Devices and Radiological Health. Dr. Sengupta is supported by grants from the National Institute of Health/National Heart, Lung, and Blood Institute (1R01HL173998-01A1, 3U01HL088942-17S, 1P50MD017356-01) and National Science Foundation (#2125872). He has served on the Advisory Board of RCE Technologies and HeartSciences and holds stock options, received grants or contracts from RCE Technologies, HeartSciences, Butterfly, and MindMics, and holds patents with Mayo Clinic (US8328724B2), HeartSciences (US11445918B2), and Rutgers Health (62/864,771; US202163152686P; WO2022182603A1; US202163211829P; WO2022266288A1; US202163212228P). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Statement
Dr. Tokodi was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences and implemented the MILAB project (Project No. RRF-2.3.1-21-2022-00004) with support from the European Union. Dr. Kagiyama received research grants from AstraZeneca, Bristol Myers Squibb, EchoNous Inc., and AMI Inc., speaker honoraria from Eli Lilly, Novartis, Otsuka Pharmaceutical, Bristol Myers Squibb, and Boehringer-Ingelheim, and was affiliated with a department funded by Paramount Bed Ltd. Dr. Pandey is a consultant for Tricog, MedicalAI, Anumana, and Ultromics. Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore, has received research support from Novo Nordisk and Roche Diagnostics, and has served in advisory and consulting roles for various pharmaceutical and research organizations. She is the co-founder and non-executive director of Us2.ai and a co-inventor of Us2.ai patents (US 10,631,828 B1; US 10,702,247 B2; US 11,301,996 B2; US 11,446,009 B2; US 11,931,207 B2; US 12,001,939). Dr. Yanamala has received grants or contracts from MindMics, RCE Technologies, HeartSciences, and Abiomed, consulting fees from Turnkey Learning and Turnkey Insights, and honoraria or travel support from West Virginia University and the National Science Foundation. She is an advisor to Research Spark Hub and Magnetic 3D, a faculty member at Carnegie Mellon University, an editorial board member of the American Society of Echocardiography, and a special government employee at the FDA Center for Devices and Radiological Health. Dr. Sengupta is supported by grants from the National Institute of Health/National Heart, Lung, and Blood Institute (1R01HL173998-01A1, 3U01HL088942-17S, 1P50MD017356-01) and National Science Foundation (#2125872). He has served on the Advisory Board of RCE Technologies and HeartSciences and holds stock options, received grants or contracts from RCE Technologies, HeartSciences, Butterfly, and MindMics, and holds patents with Mayo Clinic (US8328724B2), HeartSciences (US11445918B2), and Rutgers Health (62/864,771; US202163152686P; WO2022182603A1; US202163211829P; WO2022266288A1; US202163212228P). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review boards of the ARIC field centers gave ethical approval for this work, and all participants in the ARIC cohort study provided written informed consent. The corresponding institutional review boards gave ethical approval for the two US-based prospective studies used for hemodynamic validation, and written informed consent was obtained from all patients. Institutional review boards of each participating center gave ethical approval for data collection and analysis in the multicenter Japanese registry. Given the retrospective observational design, written informed consent was waived, and an opt-out consent procedure was implemented. Institutional Review Board of Rutgers Biomedical and Health Sciences gave ethical approval for this work (study identification number: Pro2021001505).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
FUNDING SUPPORT AND AUTHOR DISCLOSURES: Dr. Tokodi was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences and implemented the MILAB project (Project No. RRF-2.3.1-21-2022-00004) with support from the European Union. Dr. Kagiyama received research grants from AstraZeneca, Bristol Myers Squibb, EchoNous Inc., and AMI Inc., speaker honoraria from Eli Lilly, Novartis, Otsuka Pharmaceutical, Bristol Myers Squibb, and Boehringer-Ingelheim, and was affiliated with a department funded by Paramount Bed Ltd. Dr. Pandey is a consultant for Tricog, MedicalAI, Anumana, and Ultromics. Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore, has received research support from Novo Nordisk and Roche Diagnostics, and has served in advisory and consulting roles for various pharmaceutical and research organizations. She is the co-founder and non-executive director of Us2.ai and a co-inventor of Us2.ai patents (US 10,631,828 B1; US 10,702,247 B2; US 11,301,996 B2; US 11,446,009 B2; US 11,931,207 B2; US 12,001,939). Dr. Yanamala has received grants or contracts from MindMics, RCE Technologies, HeartSciences, and Abiomed, consulting fees from Turnkey Learning and Turnkey Insights, and honoraria or travel support from West Virginia University and the National Science Foundation. She is an advisor to Research Spark Hub and Magnetic 3D, a faculty member at Carnegie Mellon University, an editorial board member of the American Society of Echocardiography, and a special government employee at the FDA Center for Devices and Radiological Health. Dr. Sengupta is supported by grants from the National Institute of Health/National Heart, Lung, and Blood Institute (1R01HL173998-01A1, 3U01HL088942-17S, 1P50MD017356-01) and National Science Foundation (#2125872). He has served on the Advisory Board of RCE Technologies and HeartSciences and holds stock options, received grants or contracts from RCE Technologies, HeartSciences, Butterfly, and MindMics, and holds patents with Mayo Clinic (US8328724B2), HeartSciences (US11445918B2), and Rutgers Health (62/864,771; US202163152686P; WO2022182603A1; US202163211829P; WO2022266288A1; US202163212228P). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Data Availability
The data used in this study are not publicly available because of Institutional Review Board (IRB) restrictions and participant privacy considerations. De-identified analytical results and supporting materials can be made available from the corresponding author upon reasonable request, subject to applicable ethical and institutional approvals.
